ADMA Biologics gets FDA label expansion for ASCENIV

Key facts

• ADMA Biologics received FDA label expansion for ASCENIV.
• The expanded approval includes treatment for primary immunodeficiency in children and adults.

The U.S. Food and Drug Administration (FDA) has granted ADMA Biologics an expanded label for its product ASCENIV. This approval broadens the therapeutic use of ASCENIV to include the treatment of primary immunodeficiency, a group of genetic disorders that affect the immune system, in both pediatric and adult patient populations.